

RealRate

PHARMACEUTICAL 2019

Jazz Pharmaceuticals plc Rank 12 of 363









PHARMACEUTICAL 2019



Jazz Pharmaceuticals plc Rank 12 of 363 Jazz Pharmaceuticals

The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 89% points. The greatest weakness of Jazz Pharmaceuticals plc is the variable Assets, Current, reducing the Economic Capital Ratio by 6.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 316%, being 279% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	1,234,005
Cost of Goods Sold	0
Intangible Assets	3,658,964
Liabilities, Current	345,487
Liabilities, Non-Current	0
Other Assets	110,164
Other Compr. Net Income	-56,966
Other Expenses	446,100
Other Liabilities	0
Other Net Income	-87,578
Other Revenues	1,890,922
Property and Equipment	200,358
Research and Development	226,616
Selling, General and Administrative Expense	683,530

Output Variable	Value in 1000 USD
Assets	5,203,491
Liabilities	345,487
Expenses	1,356,246
Revenues	1,890,922
Stockholders Equity	4,858,004
Net Income	447,098
Comprehensive Net Income	418,615
Economic Capital Ratio	316%

